Save Rare Treatments Task Force
Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.
Based in DC
AI Overview
With $440K in lobbying spend across 10 quarterly filings, Save Rare Treatments Task Force is an active lobbying client. Their lobbying covers 1 issue area. Active from 2023 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $10K |
| 2024 | $220K |
| 2025 | $210K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Save Rare Treatments Task Force disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.